Carlos Bais

Dr. Carlos Bais joined Inhibrx as the Executive Vice President of Translational Sciences in May 2022. Dr. Bais brings extensive scientific, drug-development, and managerial experience leading large teams across multiple early- and late-stage oncology programs. He is particularly committed to scientific excellence in pursuit of precision medicine approaches that guide the development of new targeted treatments.

Dr. Bais began his career in industry as a research lab head at Genentech and then as a Senior Director and Principal Scientist in the oncology biomarker development department. Later he served as a Director of Translational Medicine for cancer immunotherapy at Medimmune/Astrazeneca, and most recently prior to Inhibrx, as a Senior Director and Principal Scientist in the oncology biomarker development department at Genentech/Roche. Throughout his career, Dr. Bais led impactful research and translational strategies for multiple late-stage programs that resulted in high impact publications and drug approvals in diagnostic-positive patient subpopulations. Some of the drugs Dr. Bais and his team supported included Astrazeneca’s Durvalumab (anti-PD-L1) and Tremelimumab (anti-CTLA-4), and Roche’s Atezoluzimab (anti-PD-L1), Tiragolumab (anti-Tigit), and Bevacizumab (Avastin, anti-VEGF) as well as overseeing biomarker support for early-stage drug candidate development, including T-cell engagers and therapies, along with individualized neoantigen cancer vaccines.

Dr. Bais holds a Ph.D. from the University of Buenos Aires in Argentina. He received his postdoctoral training at Columbia University in New York.